SeaCrest Wealth Management LLC Invests $1.54 Million in Eli Lilly and Co (LLY) Stock

SeaCrest Wealth Management LLC acquired a new stake in shares of Eli Lilly and Co (NYSE:LLY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,259 shares of the company’s stock, valued at approximately $1,542,000.

Other institutional investors have also recently modified their holdings of the company. Accredited Investors Inc. lifted its stake in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after purchasing an additional 14 shares in the last quarter. Sfmg LLC raised its position in shares of Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after buying an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in shares of Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after buying an additional 24 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in shares of Eli Lilly and by 0.8% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after buying an additional 24 shares in the last quarter. Finally, BSW Wealth Partners raised its position in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after buying an additional 27 shares in the last quarter. 76.45% of the stock is owned by institutional investors.

Several analysts have recently issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group reissued a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly and in a research report on Friday, February 2nd. Leerink Swann increased their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and upped their target price for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Finally, Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $92.02.

Eli Lilly and Co (NYSE:LLY) traded up $2.02 during trading hours on Friday, reaching $76.23. 8,923,892 shares of the company were exchanged, compared to its average volume of 6,073,832. Eli Lilly and Co has a 12 month low of $73.69 and a 12 month high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $83,936.48, a PE ratio of -381.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $0.95 earnings per share. equities analysts anticipate that Eli Lilly and Co will post 4.88 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,039.95%.

In related news, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 259,610 shares of company stock valued at $22,727,406. Corporate insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “SeaCrest Wealth Management LLC Invests $1.54 Million in Eli Lilly and Co (LLY) Stock” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://stocknewstimes.com/2018/02/11/seacrest-wealth-management-llc-acquires-shares-of-18259-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply